Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation

Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation

We analyzed potential biomarkers of response to ibrutinib plus nivolumab in biopsies from patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Richter's transformation (RT) from the LYM1002 phase I/IIa study, using programmed death ligand 1 (PD-L1) immunohistochemi...

Full description

Bibliographic Details
Main Authors: Brendan P. Hodkinson, Michael Schaffer, Joshua D. Brody, Wojciech Jurczak, Cecilia Carpio, Dina Ben-Yehuda, Irit Avivi, Ann Forslund, Muhit Özcan, John Alvarez, Rob Ceulemans, Nele Fourneau, Anas Younes, Sriram Balasubramanian
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Translational Oncology
Subjects:
Ibrutinib
Nivolumab
Non-hodgkin's lymphoma
Biomarkers
Phase I/II trial
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523320304691

Internet

http://www.sciencedirect.com/science/article/pii/S1936523320304691

Similar Items